Improving CAR T cell therapy for small cell lung cancer
Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer
This study is testing a new way to make CAR T cell therapy better for people with small cell lung cancer by teaching the immune cells to find and attack the cancer more effectively, so patients can have better treatment results.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11064906 on NIH RePORTER |
What this research studies
This research focuses on enhancing CAR T cell therapy, a treatment that modifies a patient's own immune cells to better target and kill cancer cells. The approach involves creating CAR T cells that can recognize two specific proteins found on small cell lung cancer (SCLC) cells, while also equipping them with additional features to boost their effectiveness in the challenging tumor environment. By addressing the ways SCLC can evade immune attacks, this research aims to improve outcomes for patients with this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with small cell lung cancer who have not responded to standard treatments.
Not a fit: Patients with other types of cancer or those who do not have small cell lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with small cell lung cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise with CAR T cell therapies in hematological cancers, but this approach for solid tumors like SCLC is still being explored.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Brentjens, Renier Joseph — Roswell Park Cancer Institute Corp
- Study coordinator: Brentjens, Renier Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.